Aldeyra Therapeu Stock Price, News & Analysis

Aldeyra Therapeutics (Nasdaq: ALDX) provided business updates and financial results for 2020. The company is advancing reproxalap in pivotal Phase 3 trials for dry eye disease and allergic conjunctivitis, vital markets in ophthalmology. Key highlights include completed enrollment in the INVIGORATE trial and finalized design of the TRANQUILITY trial. Aldeyra raised $74.7 million from an underwritten public offering, enhancing its financial position. The net loss for 2020 was $37.6 million, an improvement from $60.8 million in 2019, with R&D expenses significantly reduced.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that CEO Todd C. Brady, M.D., Ph.D. will discuss reproxalap as a novel treatment for dry eye disease at the Ophthalmology Innovation Summit’s Dry Eye Disease Innovation Showcase on March 11, 2021, from 1:00 p.m. to 4:00 p.m. ET. The virtual event features market overviews, company presentations, and expert panel discussions on the dry eye disease market. Registration is free. Aldeyra is focused on developing therapies for immune-mediated diseases and is conducting Phase 3 trials for reproxalap and other investigational compounds.

Aldeyra Therapeutics (Nasdaq: ALDX) will hold a conference call on March 11, 2021, at 8:00 a.m. ET to discuss its financial results for the year ending December 31, 2020, along with business highlights. Interested parties can join via dial-in or through a live webcast available on the company’s Investors & Media page. Aldeyra is a clinical-stage biotech company focused on developing therapies targeting immune-mediated diseases, with key compounds in clinical trials for conditions such as dry eye disease and COVID-19.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that President and CEO Todd C. Brady, M.D., Ph.D. will participate in fireside conversations at two upcoming conferences: the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET, and the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 9:20 a.m. ET. These events will be archived on the company's Investor & Media page for 90 days after the presentations. Aldeyra focuses on developing therapies for immune-mediated diseases.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that Todd C. Brady, M.D., Ph.D., President and CEO, will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 3:40 p.m. ET. A live webcast of the presentation will be available on their investor relations page, and it will remain archived for 90 days. Aldeyra is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases, with investigational compounds like reproxalap and ADX-629 targeting reactive aldehyde species.

Aldeyra Therapeutics (Nasdaq: ALDX) has finalized the Phase 3 TRANQUILITY Trial design for its 0.25% reproxalap ophthalmic solution aimed at treating dry eye disease. The primary endpoint is ocular redness improvement over 90 minutes in a dry eye chamber, with approximately 150 patients per arm. Results from the run-in cohort indicated a significant decline in tear RASP levels after reproxalap administration, confirming its mechanism of action. The TRANQUILITY and TRANQUILITY-2 trials are expected to begin in H1 2021, with results anticipated in the second half of the year.

Aldeyra Therapeutics (Nasdaq: ALDX) announced the closing of its public offering of 7,868,421 common stock shares at a price of $9.50 each, raising approximately $74.7 million in gross proceeds. The shares included 1,026,315 sold due to underwriters' exercised options. Funds will be used for the development of reproxalap, other product candidates, and general corporate purposes. Jefferies LLC and SVB Leerink LLC managed the offering. The offering was registered under a shelf registration statement with the SEC.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) has announced an underwritten public offering of 6,842,106 shares at $9.50 each, aiming for approximately $65.0 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 1,026,315 shares. Proceeds will support the development of Aldeyra's lead compound, reproxalap, alongside other candidates and general corporate needs. The transaction is expected to close by January 19, 2021, pending customary conditions.

Aldeyra Therapeutics (Nasdaq: ALDX) announced a proposed public offering of its common stock, with underwriters receiving a 30-day option to purchase an additional 15%. The offering aims to raise funds for the development of Aldeyra's lead compound reproxalap, among other product candidates, as well as for working capital and corporate purposes. All shares will be sold by Aldeyra under a previously filed shelf registration statement. Jefferies LLC and SVB Leerink LLC are the joint book-running managers for this offering.